Ladenburg Thalmann Maintains Buy on Corvus Pharma, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Ladenburg Thalmann analyst Aydin Huseynov maintains a Buy rating on Corvus Pharma (NASDAQ:CRVS) and raises the price target from $4 to $10.
May 30, 2023 | 11:08 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ladenburg Thalmann analyst Aydin Huseynov maintains a Buy rating on Corvus Pharma and raises the price target from $4 to $10.
The news of Ladenburg Thalmann maintaining a Buy rating on Corvus Pharma and raising the price target from $4 to $10 is positive for the stock. This indicates that the analyst has a bullish outlook on the company, which could lead to increased investor interest and a potential short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100